Compare Novartis with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SUVEN LIFESCIENCES - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SUVEN LIFESCIENCES NOVARTIS/
SUVEN LIFESCIENCES
 
P/E (TTM) x 512.7 19.4 2,637.6% View Chart
P/BV x 29.7 3.9 755.1% View Chart
Dividend Yield % 1.5 0.5 287.2%  

Financials

 NOVARTIS   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    NOVARTIS
Mar-18
SUVEN LIFESCIENCES
Mar-19
NOVARTIS/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs758338 224.5%   
Low Rs579169 341.8%   
Sales per share (Unadj.) Rs228.452.1 438.1%  
Earnings per share (Unadj.) Rs31.76.8 464.6%  
Cash flow per share (Unadj.) Rs32.88.6 382.3%  
Dividends per share (Unadj.) Rs10.001.50 666.7%  
Dividend yield (eoy) %1.50.6 252.9%  
Book value per share (Unadj.) Rs297.165.3 455.1%  
Shares outstanding (eoy) m24.69127.28 19.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.9 60.2%   
Avg P/E ratio x21.137.1 56.7%  
P/CF ratio (eoy) x20.429.6 69.0%  
Price / Book Value ratio x2.23.9 57.9%  
Dividend payout %31.522.0 143.5%   
Avg Mkt Cap Rs m16,50532,272 51.1%   
No. of employees `0000.71.1 61.7%   
Total wages/salary Rs m1,445661 218.6%   
Avg. sales/employee Rs Th8,441.36,132.2 137.7%   
Avg. wages/employee Rs Th2,163.6611.1 354.1%   
Avg. net profit/employee Rs Th1,173.1803.5 146.0%   
INCOME DATA
Net Sales Rs m5,6396,635 85.0%  
Other income Rs m1,718242 709.2%   
Total revenues Rs m7,3576,877 107.0%   
Gross profit Rs m-631,604 -3.9%  
Depreciation Rs m25221 11.4%   
Interest Rs m5538 146.7%   
Profit before tax Rs m1,5751,587 99.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792718 110.3%   
Profit after tax Rs m784869 90.1%  
Gross profit margin %-1.124.2 -4.6%  
Effective tax rate %50.345.2 111.1%   
Net profit margin %13.913.1 106.1%  
BALANCE SHEET DATA
Current assets Rs m9,5226,232 152.8%   
Current liabilities Rs m3,2961,490 221.2%   
Net working cap to sales %110.471.5 154.5%  
Current ratio x2.94.2 69.1%  
Inventory Days Days3786 42.4%  
Debtors Days Days2883 34.4%  
Net fixed assets Rs m464,043 1.1%   
Share capital Rs m123127 96.9%   
"Free" reserves Rs m7,2138,183 88.1%   
Net worth Rs m7,3368,310 88.3%   
Long term debt Rs m018 0.0%   
Total assets Rs m11,10510,389 106.9%  
Interest coverage x29.543.1 68.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.6 79.5%   
Return on assets %7.68.7 86.5%  
Return on equity %10.710.5 102.1%  
Return on capital %22.219.5 113.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m615,622 1.1%   
Fx outflow Rs m3,6301,799 201.7%   
Net fx Rs m-3,5703,822 -93.4%   
CASH FLOW
From Operations Rs m1,610356 452.9%  
From Investments Rs m687-279 -246.6%  
From Financial Activity Rs m-2,677-225 1,189.0%  
Net Cashflow Rs m-380-148 256.1%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.0 -  
FIIs % 1.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 36.5 58.9%  
Shareholders   41,647 37,287 111.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   J.B.CHEMICALS  ALEMBIC LTD  DR. REDDYS LAB  DIVIS LABORATORIES  FULFORD INDIA  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 20, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - DR. DATSONS LABS COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS